APEIRON Capital Ltd has filed its most recent 13F-HR, disclosing total holdings valued at approximately $73.65 million as of September 30, 2026. This filing is significant as it provides insight into the company's investment strategy and market positioning.

APEIRON Capital Ltd, incorporated in Hong Kong, is categorized as an investment firm. The company has been actively filing reports with the SEC, with its latest submission dated November 4, 2026, and its previous filings dating back to August 6, 2026.

The filing indicates that APEIRON's portfolio includes several notable investments. The report lists seven different holdings, with significant stakes in Nektar Therapeutics, ON Holding AG, QFIN Holdings Inc, Seagate Technology Holdings, Taiwan Semiconductor, Trip.com Group Ltd, and Western Digital Corp. The largest holding reported is in ON Holding AG, valued at approximately $28.19 million.

This update may affect various stakeholders, including investors and analysts monitoring APEIRON's activities and the broader investment community. The detailed breakdown of the company's holdings reflects its strategic focus on sectors such as biotechnology and technology.

As for what’s next, the filing does not specify any upcoming actions or decisions that APEIRON Capital Ltd plans to take following this report.

Portfolio Composition

APEIRON Capital Ltd's portfolio is diversified across several sectors, with a notable emphasis on biotechnology and technology. The company holds 51,400 shares of Nektar Therapeutics, valued at approximately $3.59 million, reflecting its interest in innovative therapeutic solutions. Additionally, APEIRON's investment in QFIN Holdings Inc amounts to 976,185 shares, valued at around $14.63 million, indicating a strong position in the financial technology sector.

In the technology sector, APEIRON has invested in Seagate Technology Holdings with a holding of 5,000 shares, valued at approximately $4.82 million, and Taiwan Semiconductor with 22,200 shares worth about $10.57 million. This strategic allocation suggests a focus on companies that are pivotal in data storage and semiconductor manufacturing.

The portfolio also includes a smaller investment in Trip.com Group Ltd, with 8,936 shares valued at approximately $356,010, indicating a cautious approach towards the travel and tourism sector.

Management and Governance

The filing is signed by Wanyi Yao, who serves as the Director of APEIRON Capital Ltd. This adds a layer of accountability and transparency to the firm's operations, as the director's contact information is provided, allowing stakeholders to engage directly with management if needed.

"The strategic focus on biotechnology and technology sectors reflects APEIRON's commitment to investing in high-growth potential areas, aligning with market trends and future demands."

While the filing provides a comprehensive overview of the current holdings, it does not include any details regarding the company's investment philosophy or future outlook, which could offer further insights into APEIRON's strategic direction.